



- Công bố khoa học và công nghệ Việt Nam
76
Ung thư học và phát sinh ung thư
Nguyễn Ngọc Quang, Phạm Quang Long, Vương Diệu Linh(1)
Phân tích đặc điểm một số biến đổi di truyền ở bệnh nhân ung thư biểu mô tuyến của phổi
Analysis characteristics of genetic alterations in lung adenocarcinoma
Tạp chí Y học Việt Nam (Tổng hội Y học Việt Nam)
2022
CD4
134-140
1859-1868
TTKHCNQG, CVv 46
- [1] Shi Y, Li J, Zhang S, et al. (2015), Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology – Mainland China Subset Analysis of the PIONEER study,PLoS ONE
- [2] Quang N, Linh V, Van-Long T (2019), Genetic and epigenetic alterations of the EGFR and mutually independent association with BRCA1, MGMT, and RASSF1A methylations in Vietnamese lung adenocarcinomas,Pathology – Research and Practice
- [3] Zhenya T, Jianjun Z, Xinyan L, et al. (2018), Coexistent genetic alterations involving ALK, RET, ROS1 or MET in 15 cases of lung adenocarcinoma,Modern Pathology
- [4] Lee GD, Lee SE, Oh DY, et al. (2017), MET exon 14 skipping mutations in lung adenocarcinoma: clinicopathologic implications and prognostic values,Journal of Thoracic Oncology
- [5] Subbiah V, Gainor JF, Rahal R, et al. (2018), Precision targeted therapy with BLU-667 for RET-driven cancers,Cancer Discovery
- [6] Wang R, Hu H, Pan Y, et al. (2012), RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer,Journal of Clinical Oncology
- [7] Gainor JF, Shaw AT (2013), The new kid on the block: RET in lung cancer,Cancer Discovery
- [8] Zhang S, Yan B, Zheng J, et al. (2016), Gene status and clinicopathologic characteristics of lung adenocarcinomas with mediastinal lymph node metastasis,Oncotarget
- [9] Stumpfova M, Jänne PA (2012), Zeroing in on ROS1 rearrangements in non-small cell lung cancer,Clinical Cancer Research
- [10] Shaw AT, Kim TM, Crinò L, et al. (2017), Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial,Lancet Oncology
- [11] Solomon BJ, Kim DW, Wu YL, et al. (2018), Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non-small-cell lung cancer,Journal of Clinical Oncology
- [12] Soda M, Choi YL, Enomoto M, et al. (2007), Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer,Nature
- [13] Freddie Bray, Andrew G, Ming S, Mary B, et al. (2021), 2021 WHO Classification of Lung Tumors,Journal of Thoracic Oncology
- [14] Hyuna S, Jacques F, Rebecca S, et al. (2021), Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,CA: A Cancer Journal for Clinicians
- [15] David K, Spasenija S, Sacha I (2021), Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations,Cancers